Analysis
CVS Health plans to split into two independent, publicly traded companies, separating its roughly 9,000 CVS Pharmacy stores from Aetna, CVS Caremark and its care-delivery businesses, the company announced on November 4, 2026. The separation is intended to be tax-free to shareholders and is expected to be completed in the first half of 2028. CVS stock fell more than 10% on the announcement, Yahoo Finance reported.
What each new CVS company gets
The press release splits the business this way:
- CVS Health (healthcare solutions): Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. David Joyner, chairman and CEO of today's CVS Health, stays on as its chairman and CEO.
- CVS Pharmacy (retail pharmacy and community health): about 9,000 pharmacies, mail pharmacy, MinuteClinic including virtual care, and the Health100 technology business. Prem Shah, currently group president, becomes CEO.
“The deal still needs final board approval, an effective Form 10 registration statement with the SEC and confirmation of the tax-free treatment.”
Shareholders will own shares of both companies. The deal still needs final board approval, an effective Form 10 registration statement with the SEC and confirmation of the tax-free treatment. Goldman Sachs is lead financial and strategic advisor, Consello is also advising, and Wachtell, Lipton, Rosen & Katz is legal counsel. CVS says both companies should carry a solid investment-grade rating and pay a dividend.
Why is CVS splitting up?
Joyner said CVS is acting "from a position of strength" after two years of rebuilding its leadership team and finances. Regulation is the other driver. Congress enacted PBM reforms in February that change how benefit managers are paid in Medicare Part D, and Arkansas and Tennessee passed laws prohibiting PBM ownership of pharmacies, AJMC reported. An analyst note cited by AJMC said the move may address "relentless state legislative scrutiny". The split unwinds the strategy behind CVS's 2018 purchase of Aetna, a $78 billion deal per AJMC.
CVS Q3 2026 earnings by segment
CVS paired the plan with third-quarter results. Total revenue rose 5.4% to $108.4 billion and adjusted EPS rose to $2.09 from $1.60, per its earnings release.
It raised full-year 2026 adjusted EPS guidance to at least $8.20, from a prior range of $7.90 to $8.10.
- Health Care Benefits (Aetna): revenue of $36.9 billion, up 2.4%; adjusted operating income of $912 million versus $314 million; medical benefit ratio of 91.3% versus 92.8%.
- Health Services (Caremark and care delivery): revenue of $54.0 billion, up 9.5%; adjusted operating income of $2.1 billion.
- Pharmacy & Consumer Wellness (the future CVS Pharmacy): revenue of $35.5 billion, down 2.0%; adjusted operating income of $1.6 billion, up 10.6%; 470.0 million prescriptions filled.
The case against the breakup
The retail side is the weaker grower on these numbers. Pharmacy & Consumer Wellness revenue fell 2.0%, which CVS tied to regulatory price cuts on certain drugs, new generics and reimbursement pressure. Leerink Partners analyst Michael Cherny argued the retail business has been "gaining market share and seeing gross margins stabilize" under CVS's CostVantage pricing model, per AJMC. CVS's own risk factors warn that the split may not happen on this timeline, may not qualify as tax-free, and may cost more in dis-synergies than estimated. AJMC put CVS's market value at $117 billion.
Health care rarely shows up in Pulse's funding tracker, but our read is that the split widens the buyer and partner list for digital-health startups: CVS Pharmacy says it will pursue partnerships with payers, pharmacy benefit managers and manufacturers, with its nearly 30,000 pharmacists as the distribution. The next hard checkpoint is the Form 10, which has to become effective before the 2028 separation can close.